LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article: Aligning Cancer Research Priorities in Europe with Recommendations for Conquering Cancer: A Comprehensive Analysis.

Horgan, Denis / Bulcke, Marc Van den / Malapelle, Umberto / Normanno, Nicola / Capoluongo, Ettore D / Prelaj, Arsela / Rizzari, Carmelo / Stathopoulou, Aliki / Singh, Jaya / Kozaric, Marta / Dube, France / Ottaviano, Manuel / Boccia, Stefania / Pravettoni, Gabriella / Cattaneo, Ivana / Malats, Núria / Buettner, Reinhard / Lekadir, Karim / de Lorenzo, Francesco /

Blanc, Patricia / Alix-Panabieres, Catherine / Badreh, Sara / Hofman, Paul / Solary, Eric / De Maria, Ruggero

Healthcare (Basel, Switzerland)

2024 Volume 12, Issue 2

Abstract: Improvements in cancer care require a new degree of collaboration beyond the purely medical sphere, extending deeply into the world of other stakeholders-preeminently patients but also the other stakeholders in the hardware and software of care. Cancer ... ...

Abstract	Improvements in cancer care require a new degree of collaboration beyond the purely medical sphere, extending deeply into the world of other stakeholders-preeminently patients but also the other stakeholders in the hardware and software of care. Cancer remains a global health challenge, necessitating collaborative efforts to understand, prevent, and treat this complex disease. To achieve this goal, a comprehensive analysis was conducted, aligning the prioritization of cancer research measures in 13 European countries with 13 key recommendations for conquering cancer in the region. The study utilized a survey involving both patients and citizens, alongside data from IQVIA, a global healthcare data provider, to assess the availability and access to single-biomarker tests in multiple European countries. The results revealed a focused approach toward understanding, preventing, and treating cancer, with each country emphasizing specific research measures tailored to its strengths and healthcare objectives. This analysis highlights the intricate relationship between research priorities, access to biomarker tests, and financial support. Timely access to tests and increased availability positively influence research areas such as cancer prevention, early detection, ageing, and data utilization. The alignment of these country-specific measures with 13 recommendations for conquering cancer in Europe underscores the importance of tailored strategies for understanding, preventing, and treating cancer.
Language	English
Publishing date	2024-01-19
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2721009-1
ISSN	2227-9032
ISSN	2227-9032
DOI	10.3390/healthcare12020259
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Demographic Analysis of Cancer Research Priorities and Treatment Correlations.

Horgan, Denis / Van den Bulcke, Marc / Malapelle, Umberto / Normanno, Nicola / Capoluongo, Ettore D / Prelaj, Arsela / Rizzari, Carmelo / Stathopoulou, Aliki / Singh, Jaya / Kozaric, Marta / Dube, France / Ottaviano, Manuel / Boccia, Stefania / Pravettoni, Gabriella / Cattaneo, Ivana / Malats, Núria / Buettner, Reinhard / Lekadir, Karim / de Lorenzo, Francesco /

Alix-Panabieres, Catherine / Badreh, Sara / Solary, Eric / De Maria, Ruggero / Hofman, Paul

Current oncology (Toronto, Ont.)

2024 Volume 31, Issue 4, Page(s) 1839–1864

Abstract: Understanding the diversity in cancer research priorities and the correlations among different treatment modalities is essential to address the evolving landscape of oncology. This study, conducted in collaboration with the European Cancer Patient ... ...

Abstract	Understanding the diversity in cancer research priorities and the correlations among different treatment modalities is essential to address the evolving landscape of oncology. This study, conducted in collaboration with the European Cancer Patient Coalition (ECPC) and Childhood Cancer International-Europe (CCI-E) as part of the "UNCAN.eu" initiative, analyzed data from a comprehensive survey to explore the complex interplay of demographics, time since cancer diagnosis, and types of treatments received. Demographic analysis revealed intriguing trends, highlighting the importance of tailoring cancer research efforts to specific age groups and genders. Individuals aged 45-69 exhibited highly aligned research priorities, emphasizing the need to address the unique concerns of middle-aged and older populations. In contrast, patients over 70 years demonstrated a divergence in research priorities, underscoring the importance of recognising the distinct needs of older individuals in cancer research. The analysis of correlations among different types of cancer treatments underscored the multidisciplinary approach to cancer care, with surgery, radiotherapy, chemotherapy, precision therapy, and biological therapies playing integral roles. These findings support the need for personalized and combined treatment strategies to achieve optimal outcomes. In conclusion, this study provides valuable insights into the complexity of cancer research priorities and treatment correlations in a European context. It emphasizes the importance of a multifaceted, patient-centred approach to cancer research and treatment, highlighting the need for ongoing support, adaptation, and collaboration to address the ever-changing landscape of oncology.
MeSH term(s)	Humans ; Neoplasms/therapy ; Male ; Aged ; Middle Aged ; Female ; Biomedical Research ; Adult ; Demography ; Research ; Europe
Language	English
Publishing date	2024-03-29
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	1236972-x
ISSN	1718-7729 ; 1198-0052
ISSN (online)	1718-7729
ISSN	1198-0052
DOI	10.3390/curroncol31040139
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4305: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: European Health Data Space-An Opportunity Now to Grasp the Future of Data-Driven Healthcare.

Horgan, Denis / Hajduch, Marian / Vrana, Marilena / Soderberg, Jeannette / Hughes, Nigel / Omar, Muhammad Imran / Lal, Jonathan A / Kozaric, Marta / Cascini, Fidelia / Thaler, Verena / Solà-Morales, Oriol / Romão, Mário / Destrebecq, Frédéric / Sky Gross, Edith

Healthcare (Basel, Switzerland)

2022 Volume 10, Issue 9

Abstract: The May 2022 proposal from the European commission for a 'European health data space' envisages advantages for health from exploiting the growing mass of health data in Europe. However, key stakeholders have identified aspects that demand clarification ... ...

Abstract	The May 2022 proposal from the European commission for a 'European health data space' envisages advantages for health from exploiting the growing mass of health data in Europe. However, key stakeholders have identified aspects that demand clarification to ensure success. Data will need to be freed from traditional silos to flow more easily and to cross artificial borders. Wide engagement will be necessary among healthcare professionals, researchers, and the patients and citizens that stand to gain the most but whose trust must be won if they are to allow use or transfer of their data. This paper aims to alert the wider scientific community to the impact the ongoing discussions among lawmakers will have. Based on the literature and the consensus findings of an expert multistakeholder panel organised by the European Alliance for Personalised Medicine (EAPM) in June 2022, it highlights the key issues at the intersection of science and policy, and the potential implications for health research for years, perhaps decades, to come.
Language	English
Publishing date	2022-08-26
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2721009-1
ISSN	2227-9032
ISSN	2227-9032
DOI	10.3390/healthcare10091629
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Making Sure That Orphan Incentives Tip the Right Way in Europe.

Horgan, Denis / Koeva-Balabanova, Jasmina / Capoluongo, Ettore / Jagielska, Beata / Cattaneo, Ivana / Kozaric, Marta / Tumiene, Birute / El Ahl, Jean-Paul / Lal, Jonathan A / Kalra, Dipak / Malats, Núria

Healthcare (Basel, Switzerland)

2022 Volume 10, Issue 9

Abstract: The delicate balance of funding research and development of treatments for rare disease is only imperfectly achieved in Europe, and even the current provisional equilibrium is under a new threat from well-intentioned policy changes now in prospect that ... ...

Abstract	The delicate balance of funding research and development of treatments for rare disease is only imperfectly achieved in Europe, and even the current provisional equilibrium is under a new threat from well-intentioned policy changes now in prospect that could-in addition to the intrinsic complexities of research-reduce the incentives on which commercial activity in this area is dependent. The European Union review of its pharmaceutical legislation, for which proposals are scheduled to appear before the end of 2022, envisages adjusting the decade-old incentives to meet objectives that are more precisely targeted. However, researchers, physicians, patients and industry have expressed concerns that ill-considered modifications could have unintended consequences in disrupting the current balance and could reduce rather than increase the flow of innovative treatments for rare diseases.
Language	English
Publishing date	2022-08-23
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2721009-1
ISSN	2227-9032
ISSN	2227-9032
DOI	10.3390/healthcare10091600
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Tackling Thyroid Cancer in Europe-The Challenges and Opportunities.

Horgan, Denis / Führer-Sakel, Dagmar / Soares, Paula / Alvarez, Clara V / Fugazzola, Laura / Netea-Maier, Romana T / Jarzab, Barbara / Kozaric, Marta / Bartes, Beate / Schuster-Bruce, James / Dal Maso, Luigino / Schlumberger, Martin / Pacini, Furio

Healthcare (Basel, Switzerland)

2022 Volume 10, Issue 9

Abstract: Thyroid cancer (TC) is the most common malignancy of the endocrine system that affects the thyroid gland. It is usually treatable and, in most cases, curable. The central issues are how to improve knowledge on TC, to accurately identify cases at an early ...

Abstract	Thyroid cancer (TC) is the most common malignancy of the endocrine system that affects the thyroid gland. It is usually treatable and, in most cases, curable. The central issues are how to improve knowledge on TC, to accurately identify cases at an early stage that can benefit from effective intervention, optimise therapy, and reduce the risk of overdiagnosis and unnecessary treatment. Questions remain about management, about treating all patients in referral centres, and about which treatment should be proposed to any individual patient and how this can be optimised. The European Alliance for Personalised Medicine (EAPM) hosted an expert panel discussion to elucidate some of the challenges, and to identify possible steps towards effective responses at the EU and member state level, particularly in the context of the opportunities in the European Union's evolving initiatives-notably its Beating Cancer Plan, its Cancer Mission, and its research funding programmes. Recommendations emerging from the panel focus on improved infrastructure and funding, and on promoting multi-stakeholder collaboration between national and European initiatives to complement, support, and mutually reinforce efforts to improve patient care.
Language	English
Publishing date	2022-08-25
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2721009-1
ISSN	2227-9032
ISSN	2227-9032
DOI	10.3390/healthcare10091621
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Tackling Mantle Cell Lymphoma in Europe.

Horgan, Denis / Walewski, Jan / Aurer, Igor / Visco, Carlo / Giné, Eva / Fetica, Bogdan / Jerkeman, Mats / Kozaric, Marta / da Silva, Maria Gomes / Dreyling, Martin

Healthcare (Basel, Switzerland)

2022 Volume 10, Issue 9

Abstract: An expert panel convened by the European Alliance for Personalized Medicine (EAPM) reflected on achievements and outstanding challenges in Europe in mantle cell lymphoma (MCL). Through the prism of member state experience, the panel noted advances in ... ...

Abstract	An expert panel convened by the European Alliance for Personalized Medicine (EAPM) reflected on achievements and outstanding challenges in Europe in mantle cell lymphoma (MCL). Through the prism of member state experience, the panel noted advances in outcomes over the last decade, but highlighted issues constituting barriers to better care. The list notably included availability of newer treatments, infrastructure and funding for related testing, and shortages of relevant skills and of research support. The prospect of improvements was held to reside in closer coordination and cooperation within and between individual countries, and in changes in policy and scale of investment at both national and EU levels.
Language	English
Publishing date	2022-09-03
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2721009-1
ISSN	2227-9032
ISSN	2227-9032
DOI	10.3390/healthcare10091682
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring.

Horgan, Denis / Čufer, Tanja / Gatto, Francesco / Lugowska, Iwona / Verbanac, Donatella / Carvalho, Ângela / Lal, Jonathan A / Kozaric, Marta / Toomey, Sinead / Ivanov, Hristo Y / Longshore, John / Malapelle, Umberto / Hasenleithner, Samantha / Hofman, Paul / Alix-Panabières, Catherine

Healthcare (Basel, Switzerland)

2022 Volume 10, Issue 9

Abstract: Liquid biopsy (LB) is a minimally invasive method which aims to detect circulating tumor-derived components in body fluids. It provides an alternative to current cancer screening methods that use tissue biopsies for the confirmation of diagnosis. This ... ...

Abstract	Liquid biopsy (LB) is a minimally invasive method which aims to detect circulating tumor-derived components in body fluids. It provides an alternative to current cancer screening methods that use tissue biopsies for the confirmation of diagnosis. This paper attempts to determine how far the regulatory, policy, and governance framework provide support to LB implementation into healthcare systems and how the situation can be improved. For that reason, the European Alliance for Personalised Medicine (EAPM) organized series of expert panels including different key stakeholders to identify different steps, challenges, and opportunities that need to be taken to effectively implement LB technology at the country level across Europe. To accomplish a change of patient care with an LB approach, it is required to establish collaboration between multiple stakeholders, including payers, policymakers, the medical and scientific community, and patient organizations, both at the national and international level. Regulators, pharma companies, and payers could have a major impact in their own domain. Linking national efforts to EU efforts and vice versa could help in implementation of LB across Europe, while patients, scientists, physicians, and kit manufacturers can generate a pull by undertaking more research into biomarkers.
Language	English
Publishing date	2022-09-07
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2721009-1
ISSN	2227-9032
ISSN	2227-9032
DOI	10.3390/healthcare10091714
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The gaps between the new EU legislation on

Horgan, Denis / Plebani, Mario / Orth, Matthias / Macintyre, Elizabeth / Jackson, Stan / Lal, Jonathan A / Dube, France / Kozaric, Marta / Tumiene, Birute / Salgado, Roberto / Schalken, Jack A / Capoluongo, Ettore D / Carnielli, Marta

Clinical chemistry and laboratory medicine

2022 Volume 61, Issue 2, Page(s) 224–233

Abstract: The background to this debate is now well-known: an EU policy decision to tighten controls on the devices and diagnostics sector led to the adoption of a regulation in 2017 with a schedule for implementation over coming years - a timetable extended still ...

Abstract	The background to this debate is now well-known: an EU policy decision to tighten controls on the devices and diagnostics sector led to the adoption of a regulation in 2017 with a schedule for implementation over coming years - a timetable extended still further by last-minute legislation in early 2022, to provide the sector and regulators with more time to adapt to the changes. Discussions among experts organised in April by the European Alliance for Personalized Medicine (EAPM) exposed continuing challenges that cannot be fully resolved by the recent deferral of implementation deadlines. One salient problem is that there is little awareness of the
MeSH term(s)	Humans ; Europe ; Precision Medicine
Language	English
Publishing date	2022-11-22
Publishing country	Germany
Document type	Journal Article
ZDB-ID	1418007-8
ISSN	1437-4331 ; 1434-6621 ; 1437-8523
ISSN (online)	1437-4331
ISSN	1434-6621 ; 1437-8523
DOI	10.1515/cclm-2022-1051
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 121: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?

Horgan, Denis / Spanic, Tanja / Apostolidis, Kathi / Curigliano, Giuseppe / Chorostowska-Wynimko, Joanna / Dauben, Hans-Peter / Lal, Jonathan A / Dziadziuszko, Rafal / Mayer-Nicolai, Christine / Kozaric, Marta / Jönsson, Bengt / Gutierrez-Ibarluzea, Iñaki / Fandel, Marie-Helene / Lopert, Ruth

Healthcare (Basel, Switzerland)

2022 Volume 10, Issue 8

Abstract: Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that ... ...

Abstract	Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that investment in research and development (R&D) for innovative medicines and treatments is essential for making progress in preventing and treating diseases. Ahead of the legislative process, which should begin by the end of 2022, discussions focus on how Europe can best promote the huge potential benefits of new science and technology within the regulatory framework. The challenges in European healthcare were spelled out by the panellists at the roundtable organised by European Alliance for Personalised Medicine (EAPM). Outcomes from panellists' discussions have been summarized and re-arranged in this paper under five headings: innovation, unmet medical need, access, security of supply, adapting to progress, and efficiency. Some of the conclusions that emerged from the panel are a call for a better overall holistic vision of the future of pharmaceuticals and health in Europe and a collaborative effort among all stakeholders, seeing the delivery of medicines as part of a broader picture of healthcare.
Language	English
Publishing date	2022-08-22
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2721009-1
ISSN	2227-9032
ISSN	2227-9032
DOI	10.3390/healthcare10081594
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Meeting the Need for a Discussion of Unmet Medical Need.

Horgan, Denis / Borisch, Bettina / Eliasen, Bogi / Kapitein, Peter / Biankin, Andrew V / Gijssels, Stefan / Zaiac, Michael / Fandel, Marie-Helene / Lal, Jonathan A / Kozaric, Marta / Moss, Barbara / De Maria, Ruggero / Geanta, Marius / Nowak, Frédérique / Montserrat-Moliner, Antoni / Riess, Olaf

Healthcare (Basel, Switzerland)

2022 Volume 10, Issue 8

Abstract: As Europe and the world continue to battle against COVID, the customary complacency of society over future threats is clearly on display. Just 30 months ago, such a massive disruption to global lives, livelihoods and quality of life seemed unimaginable. ... ...

Abstract	As Europe and the world continue to battle against COVID, the customary complacency of society over future threats is clearly on display. Just 30 months ago, such a massive disruption to global lives, livelihoods and quality of life seemed unimaginable. Some remedial European Union action is now emerging, and more is proposed, including in relation to tackling "unmet medical need" (UMN). This initiative-directing attention to the future of treating disease and contemplating incentives to stimulate research and development-is welcome in principle. But the current approach being considered by EU officials merits further discussion, because it may prove counter-productive, impeding rather than promoting innovation. This paper aims to feed into these ongoing policy discussions, and rather than presenting research in the classical sense, it discusses the key elements from a multistakeholder perspective. Its central concern is over the risk that the envisaged support will fail to generate valuable new treatments if the legislation is phrased in a rigidly linear manner that does not reflect the serpentine realities of the innovation process, or if the definition placed on unmet medical need is too restrictive. It cautions that such an approach presumes that "unmet need" can be precisely and comprehensively defined in advance on the basis of the past. It cautions that such an approach can reinforce the comfortable delusion that the future is totally predictable-the delusion that left the world as easy prey to COVID. Instead, the paper urges reflection on how the legislation that will shortly enter the pipeline can be phrased so as to allow for the flourishing of a culture capable of rapid adaptation to the unexpected.
Language	English
Publishing date	2022-08-19
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2721009-1
ISSN	2227-9032
ISSN	2227-9032
DOI	10.3390/healthcare10081578
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito